Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

MY7 Monoclonal Antibody for Diagnosis of Cutaneous T-Cell Lymphoma

MY7 Monoclonal Antibody for Diagnosis of Cutaneous T-Cell Lymphoma Abstract • Infiltrate in cutaneous T-cell lymphomas (CTCLs) is composed mainly of CD4 helper cells with a phenotype very similar to that of benign cutaneous lymphoid infiltrate. MY7 (CD 13) is a monoclonal antibody that is normally expressed on peripheral granulocytes and monocytes but also cross-reacts with an antigen expressed on epidermal basal cells. We studied MY7 expression on basal cells of the epidermis and CD4 cell infiltrate in 34 CTCLs, 11 pseudolymphomas, and 29 other benign cutaneous lesions. An indirect immunofluorescence technique with double labeling and an immunoperoxidase technique were used. We found that in benign inflammatory infiltrate, less than 10% of CD4 cells expressed MY7 antigen associated with normal MY7 monoclonal antibody labeling of basal cells, whereas in CTCLs more than 50% of CD4 tumoral cells in dermis expressed MY7 antigens; however, basal cells were MY7 negative. Thus, it is demonstrated that MY7 monoclonal antibody with its double modulation on epidermis (basal cells) and dermis (CD4 cells) has diagnostic value for differentiating CTCLs with CD4+ MY7+ tumor cells in dermis and MY7-negative basal cells from benign inflammatory lesions with CD4+ MY7— cells in dermis and MY7-positive basal cells. This modulation of MY7 labeling could be related to the secretion of epidermal cytokines. (Arch Dermatol. 1990;126:1454-1456) References 1. Berger CL, Warburton D, Raapat J, LoGerfo P, Ebelson AZ. Cutaneous T cell lymphoma: neoplasm of T cells with helper activity . Blood . 1979;53:642-651. 2. Haydes BF, Mensley LL, Jegasothy BV. Phenotype characterization of skin infiltrating T cells in cutaneous T cell infiltrates . Blood . 1982;60:463-473. 3. Willemze R, De Gaaf-Reitsma CB, Cnossen J, Van Vloten W, Meyer C. Characterization of T cell subpopulations in skin and peripheral blood of patients with cutaneous T cell lymphomas and benign inflammatory dermatoses . J Clin Invest Dermatol. 1983; 80:60-66.Crossref 4. Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells . J Clin Invest. 1981;68:932-935.Crossref 5. Lacour JP, Verrando P, Adrien A, Ortonne JP. MY7 anticorps monoclonal marqueur de la lignée monocytaire sanguine réagit avec le cytoplasme des kératinocytes de l'assise basale . Read before the French Society of Dermatological Research; 1986; Nantes, France . 6. Hoppe RT, Fukz Z. The management of mycosis fungoides . In: Carter SK, Glatstein E, Livingston RB, eds. Principles of Cancer Treatment . New York, NY: McGraw-Hill International Book Co; 1982:685-693. 7. Wieczorek R, Burke JS, Knowles DM. Leu M1 antigen expression in T cell neoplasia . Am J Pathol. 1985;121:374-380. 8. Kadin M, Nasu K, Sako D, Said J, Vonderherd E. Lymphomatoid papulosis: a cutaneous proliferation of activated helper T cells expressing Hodgkin's disease associated antigens . Am J Pathol. 1985;119:315-325. 9. Wieczorek R, Suhrland M, Ramsay D, Reed ML, Knowles DM II. Leu M1 antigen expression in advanced (tumors) stage mycosis fungoides . Am J Clin Pathol. 1986;86:25-32. 10. Hoffman FM, Lopez D, Husmann L, Meyer PR, Taylor CR. Heterogeneity of macrophage populations in human lymphoid tissue and peripheral blood . Cell Immunol. 1984;88:61-74.Crossref 11. Tron VA, Rosenthal D, Sauder D. Epidermal interleukin-1 increased in cutaneous T cell lymphoma . J Invest Dermatol. 1988; 90:378-381.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

MY7 Monoclonal Antibody for Diagnosis of Cutaneous T-Cell Lymphoma

Loading next page...
 
/lp/american-medical-association/my7-monoclonal-antibody-for-diagnosis-of-cutaneous-t-cell-lymphoma-dTiL5DBZJj
Publisher
American Medical Association
Copyright
Copyright © 1990 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1990.01670350068009
Publisher site
See Article on Publisher Site

Abstract

Abstract • Infiltrate in cutaneous T-cell lymphomas (CTCLs) is composed mainly of CD4 helper cells with a phenotype very similar to that of benign cutaneous lymphoid infiltrate. MY7 (CD 13) is a monoclonal antibody that is normally expressed on peripheral granulocytes and monocytes but also cross-reacts with an antigen expressed on epidermal basal cells. We studied MY7 expression on basal cells of the epidermis and CD4 cell infiltrate in 34 CTCLs, 11 pseudolymphomas, and 29 other benign cutaneous lesions. An indirect immunofluorescence technique with double labeling and an immunoperoxidase technique were used. We found that in benign inflammatory infiltrate, less than 10% of CD4 cells expressed MY7 antigen associated with normal MY7 monoclonal antibody labeling of basal cells, whereas in CTCLs more than 50% of CD4 tumoral cells in dermis expressed MY7 antigens; however, basal cells were MY7 negative. Thus, it is demonstrated that MY7 monoclonal antibody with its double modulation on epidermis (basal cells) and dermis (CD4 cells) has diagnostic value for differentiating CTCLs with CD4+ MY7+ tumor cells in dermis and MY7-negative basal cells from benign inflammatory lesions with CD4+ MY7— cells in dermis and MY7-positive basal cells. This modulation of MY7 labeling could be related to the secretion of epidermal cytokines. (Arch Dermatol. 1990;126:1454-1456) References 1. Berger CL, Warburton D, Raapat J, LoGerfo P, Ebelson AZ. Cutaneous T cell lymphoma: neoplasm of T cells with helper activity . Blood . 1979;53:642-651. 2. Haydes BF, Mensley LL, Jegasothy BV. Phenotype characterization of skin infiltrating T cells in cutaneous T cell infiltrates . Blood . 1982;60:463-473. 3. Willemze R, De Gaaf-Reitsma CB, Cnossen J, Van Vloten W, Meyer C. Characterization of T cell subpopulations in skin and peripheral blood of patients with cutaneous T cell lymphomas and benign inflammatory dermatoses . J Clin Invest Dermatol. 1983; 80:60-66.Crossref 4. Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells . J Clin Invest. 1981;68:932-935.Crossref 5. Lacour JP, Verrando P, Adrien A, Ortonne JP. MY7 anticorps monoclonal marqueur de la lignée monocytaire sanguine réagit avec le cytoplasme des kératinocytes de l'assise basale . Read before the French Society of Dermatological Research; 1986; Nantes, France . 6. Hoppe RT, Fukz Z. The management of mycosis fungoides . In: Carter SK, Glatstein E, Livingston RB, eds. Principles of Cancer Treatment . New York, NY: McGraw-Hill International Book Co; 1982:685-693. 7. Wieczorek R, Burke JS, Knowles DM. Leu M1 antigen expression in T cell neoplasia . Am J Pathol. 1985;121:374-380. 8. Kadin M, Nasu K, Sako D, Said J, Vonderherd E. Lymphomatoid papulosis: a cutaneous proliferation of activated helper T cells expressing Hodgkin's disease associated antigens . Am J Pathol. 1985;119:315-325. 9. Wieczorek R, Suhrland M, Ramsay D, Reed ML, Knowles DM II. Leu M1 antigen expression in advanced (tumors) stage mycosis fungoides . Am J Clin Pathol. 1986;86:25-32. 10. Hoffman FM, Lopez D, Husmann L, Meyer PR, Taylor CR. Heterogeneity of macrophage populations in human lymphoid tissue and peripheral blood . Cell Immunol. 1984;88:61-74.Crossref 11. Tron VA, Rosenthal D, Sauder D. Epidermal interleukin-1 increased in cutaneous T cell lymphoma . J Invest Dermatol. 1988; 90:378-381.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Nov 1, 1990

References